Lidocaine-Propitocain Cream, a Eutectic Mixture of Local Anesthetics, Effectively Relieves Pain Associated With Vascular Access Intervention Therapy in Patients Undergoing Hemodialysis: A Placebo-Controlled, Double-Blind, Crossover Study

Seishi Aihara, Shunsuke Yamada, Satoru Shichijo, Kento Fukumitsu, Mika Kondo, Yutaro Hirashima, Hideaki Oka, Taro Kamimura, Atsumi Harada, Toshiaki Nakano, Kazuhiko Tsuruya, Takanari Kitazono

研究成果: ジャーナルへの寄稿記事

抄録

Vascular access intervention therapy (VAIVT) is necessary to maintain vascular access in patients undergoing hemodialysis. VAIVT-associated vasodilatation is painful. However, few reports have focused on effective pain relief at the time of VAIVT. The present study was performed to determine whether lidocaine-propitocain cream, a eutectic mixture of local anesthetics (EMLA), effectively reduces VAIVT-associated pain in patients undergoing hemodialysis. This placebo-controlled, double-blind, crossover study was conducted in a single center. Among 210 patients who underwent a total of 437 VAIVT procedures from August 2017 to June 2018, 30 patients were randomly allocated to either the EMLA–placebo arm or placebo–EMLA arm at the time of VAIVT. EMLA application significantly reduced the visual analog scale score compared with placebo (47.0 ± 21.1 vs. 68.6 ± 20.7 mm, respectively; P < 0.05). EMLA is a safe and effective treatment for relief of VAIVT-associated pain in patients undergoing hemodialysis.

元の言語英語
ジャーナルTherapeutic Apheresis and Dialysis
DOI
出版物ステータス出版済み - 1 1 2019

Fingerprint

Lidocaine
Double-Blind Method
Cross-Over Studies
Blood Vessels
Renal Dialysis
Placebos
Pain
Therapeutics
EMLA
Visual Analog Scale
Vasodilation

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

これを引用

Lidocaine-Propitocain Cream, a Eutectic Mixture of Local Anesthetics, Effectively Relieves Pain Associated With Vascular Access Intervention Therapy in Patients Undergoing Hemodialysis : A Placebo-Controlled, Double-Blind, Crossover Study. / Aihara, Seishi; Yamada, Shunsuke; Shichijo, Satoru; Fukumitsu, Kento; Kondo, Mika; Hirashima, Yutaro; Oka, Hideaki; Kamimura, Taro; Harada, Atsumi; Nakano, Toshiaki; Tsuruya, Kazuhiko; Kitazono, Takanari.

:: Therapeutic Apheresis and Dialysis, 01.01.2019.

研究成果: ジャーナルへの寄稿記事

@article{be2c15340fdc47a1ba46a807aa7d7f30,
title = "Lidocaine-Propitocain Cream, a Eutectic Mixture of Local Anesthetics, Effectively Relieves Pain Associated With Vascular Access Intervention Therapy in Patients Undergoing Hemodialysis: A Placebo-Controlled, Double-Blind, Crossover Study",
abstract = "Vascular access intervention therapy (VAIVT) is necessary to maintain vascular access in patients undergoing hemodialysis. VAIVT-associated vasodilatation is painful. However, few reports have focused on effective pain relief at the time of VAIVT. The present study was performed to determine whether lidocaine-propitocain cream, a eutectic mixture of local anesthetics (EMLA), effectively reduces VAIVT-associated pain in patients undergoing hemodialysis. This placebo-controlled, double-blind, crossover study was conducted in a single center. Among 210 patients who underwent a total of 437 VAIVT procedures from August 2017 to June 2018, 30 patients were randomly allocated to either the EMLA–placebo arm or placebo–EMLA arm at the time of VAIVT. EMLA application significantly reduced the visual analog scale score compared with placebo (47.0 ± 21.1 vs. 68.6 ± 20.7 mm, respectively; P < 0.05). EMLA is a safe and effective treatment for relief of VAIVT-associated pain in patients undergoing hemodialysis.",
author = "Seishi Aihara and Shunsuke Yamada and Satoru Shichijo and Kento Fukumitsu and Mika Kondo and Yutaro Hirashima and Hideaki Oka and Taro Kamimura and Atsumi Harada and Toshiaki Nakano and Kazuhiko Tsuruya and Takanari Kitazono",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/1744-9987.12813",
language = "English",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Lidocaine-Propitocain Cream, a Eutectic Mixture of Local Anesthetics, Effectively Relieves Pain Associated With Vascular Access Intervention Therapy in Patients Undergoing Hemodialysis

T2 - A Placebo-Controlled, Double-Blind, Crossover Study

AU - Aihara, Seishi

AU - Yamada, Shunsuke

AU - Shichijo, Satoru

AU - Fukumitsu, Kento

AU - Kondo, Mika

AU - Hirashima, Yutaro

AU - Oka, Hideaki

AU - Kamimura, Taro

AU - Harada, Atsumi

AU - Nakano, Toshiaki

AU - Tsuruya, Kazuhiko

AU - Kitazono, Takanari

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Vascular access intervention therapy (VAIVT) is necessary to maintain vascular access in patients undergoing hemodialysis. VAIVT-associated vasodilatation is painful. However, few reports have focused on effective pain relief at the time of VAIVT. The present study was performed to determine whether lidocaine-propitocain cream, a eutectic mixture of local anesthetics (EMLA), effectively reduces VAIVT-associated pain in patients undergoing hemodialysis. This placebo-controlled, double-blind, crossover study was conducted in a single center. Among 210 patients who underwent a total of 437 VAIVT procedures from August 2017 to June 2018, 30 patients were randomly allocated to either the EMLA–placebo arm or placebo–EMLA arm at the time of VAIVT. EMLA application significantly reduced the visual analog scale score compared with placebo (47.0 ± 21.1 vs. 68.6 ± 20.7 mm, respectively; P < 0.05). EMLA is a safe and effective treatment for relief of VAIVT-associated pain in patients undergoing hemodialysis.

AB - Vascular access intervention therapy (VAIVT) is necessary to maintain vascular access in patients undergoing hemodialysis. VAIVT-associated vasodilatation is painful. However, few reports have focused on effective pain relief at the time of VAIVT. The present study was performed to determine whether lidocaine-propitocain cream, a eutectic mixture of local anesthetics (EMLA), effectively reduces VAIVT-associated pain in patients undergoing hemodialysis. This placebo-controlled, double-blind, crossover study was conducted in a single center. Among 210 patients who underwent a total of 437 VAIVT procedures from August 2017 to June 2018, 30 patients were randomly allocated to either the EMLA–placebo arm or placebo–EMLA arm at the time of VAIVT. EMLA application significantly reduced the visual analog scale score compared with placebo (47.0 ± 21.1 vs. 68.6 ± 20.7 mm, respectively; P < 0.05). EMLA is a safe and effective treatment for relief of VAIVT-associated pain in patients undergoing hemodialysis.

UR - http://www.scopus.com/inward/record.url?scp=85067493292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067493292&partnerID=8YFLogxK

U2 - 10.1111/1744-9987.12813

DO - 10.1111/1744-9987.12813

M3 - Article

C2 - 31006955

AN - SCOPUS:85067493292

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

ER -